LITERATURA

1. Ailawadhi S, Sung K-W, Carlson LA, Baer MR: Serotonin syndrome cyused by interaction between citalopram and fentanyl. *J Clin Pharmacoy Therap.* 2007;32:199-202.
2. Ansari H, Kouti L. Drug interaction and serotonin toxicity with opioid use: another reason to avoid opioids in headache and migraine treatment. *Curr Pain Headache Rep.* 2016;20:60. doi: 10.1007/c11916-016-1579-3.
3. Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. *Arch Toxicol.* 2018; https://doi.org/10.1007/s00204-018-2244-6.
4. Baldo BA, Rose MA. The anaestetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. *Brit J Anaesth.* 2020;124(1):44-62.
5. Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity serotonin toxicity. *Arch Toxicol.* 2021; https://doi.org/10.1007/s00204-021-03068-2.
6. Barann M, Stamer UM, Lyutenska M, et al. Effects of opioids on human serotonin transporters. *Naunyn-Schmiedaberg's Arch Pharmacol.* 2015;388:43-49.
7. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. *Pain Med.* 2019;20:S2-S12.
8. Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. *Pain Phys.* 2015;18:395-400.
9. Boyer EW, Shannon M. The Serotonin syndrome. *N Engl J Med.* 2005;352:1112-20.
10. Dizdarevic A, Bremer N. Cervical spinal cord stimulation with concomitant serotonin norepinephrine reuptake inhibitor therapy leading to the serotonin syndrome. *Pain Med.* 2017;18:1199-1202.
11. Duma SR, Fung VSC. Drug-induced movement disorders. *Aust Prescr.* 2019;42:56-61.
12. Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: sinple and accurate diagnostic decision rules for serotonin toxicity. *Q J Med.* 2003;96:635-42.
13. FDA Drug safety communications. FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016. https ://www.fda.gov/downl oads/Drugs /DrugSafety /UCM49 1302.pdf.
14. Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). *Can Fam Phys.* 2018;64(10):720-727.
15. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The serotonin syndrome: from molecular mechanisms to clinical practice. *Int J Molecul Sci.* 2019;20:2288. doi:10.3390/ijms20092288
16. Fujáková M, Kopeček M. Antidepresiva – od teorie ke klinické praxi. *Klin Farmakol Farm.* 2012;26(1):29-37.
17. Gayle JA, Abadie JV, Kaye AM, Kaye AD. Serotonin syndrome. In: A.D. Kaye et al. (eds.), Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer Science+Business Media New York. 2015:797-807. doi: 10.1007/978-1-4614-8948-1_49.
18. Gressler LE, Hammond DA, Painter JT. Serotonin syndrome in tapentadol literature: systematic review of original research. *J Pain Palliat Care Pharmacotherapy.* 2017;31(3-4):228-236.
19. Höschl C. Neurotrofní účinky antidepresiv. Available from: http://www.hoschl.cz/files/445_cz_Neurotrofni%20AD.pdf.
20. Jones D, Story DA. Serotonin syndrome and the anaesthetist. *Anaesth Intensive Care.* 2005;33:181-87.
21. Kanova K, Kohout P. Serotonin – its synthesis and roles in the healthy and the critically ill. *Int J Med Sci.* 2021;22:4873.
22. Koury KM, Tsui B, Gulur P. Incidence of serotonine syndrome in patients treated with fentanyl on serotoninergic agents. *Pain Phys.* 2015;18:E27-E30.
23. Malcolm B, Thomas K. Serotonin toxicity of serotoninergic psychedelics. *Psychopharmacology.* 2022;239(6):1881-1891.
24. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. *Medicine.* 2000;79(4):201-209.
25. Mastroianni A, Ravaglia G. Serotonin syndrome due to co-administration of linezolid and methadone. *Infez Med.* 2017;25(3):263-66.
26. Mohr P. Serotoninový syndrom – diagnostika, terapie, prevence. *Psych Praxi.* 2001;3:117-20.
27. Nelson EM, Philbrick AM: Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors. *Ann Pharmacother.* 2012;46:1712-16.
28. Prakash S, Adroja B, Parekh H. Serotonin syndrome in patients with headache disorders. *BMJ Case Rep.* 2017. doi:10.1136/bcr-2017-221383.
29. Prakash S, Rathore C, Rana K, Patel H. Antiepileptic drugs and serotonin syndrome – a systematic review of case series and case reports. *Seizure Eur J Epil.* 2021;91:117-31.
30. Praško J, Prašková H. Farmakoterapie deprese. *Psychiat. Praxi.* 2006;5:214-224.
31. Prokeš M, Suchopár J. Serotoninový syndrom: co bychom o něm měli vědět. *Med Praxi.* 2014;11(5):226-230.
32. Rastogi R, Swarm RA, Patel TA. Case scenarion: opioid assiciation with serotonin syndrome. Implications to the practitioners. *Anesthesiology.* 2011;115(6):1291-98.
33. Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. *Brit J Prarmacol.* 2018;175:532-543.
34. Roulet L, Rollason V, Desmeules J, Piguet V. Tapentadol versus tramadol: a narrative and comparative review of ther pharmacological, efficacy and safety profiles in adult patients. *Drugs.* 2021;81:1257-72.
35. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: patophysiology, clinical features, management, and potential ruture directions. Int *J Tryptoph Res.* 2019;12(1):1-14.
36. Shelton RC. Serotonin and norepinephrine reuptake inhibitors. Handbook of Experimental Pharmacology, Springer Nature Switzerland AG 2018. Available from: https://doi.org/10.1007/164_2018_164.
37. Spadaro A, Scott KR, Koyfman A, Long B. High risk and low prevalence disease: serotonin syndrome. *Am J Emerg Med.* 2022;61:90-97.
38. SPC: Peritol 4 mg https://www.sukl.cz/modules/medication/detail.php?code=0219901 &tab=texts.
39. Tašková I. Úzkostné poruchy a jejich léčba. *Prakt Lékáren.* 2021;17(4):207-212.
40. Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. In: Romanovsky AA: Handbook of clinical neurology, 3rd Series, Elsevier 2018:663-675.
41. UpToDate 2023. Available from: https://www.uptodate.com/contents/image?imageKey=EM%2F71268.
42. Vaněk J. Serotoninový syndrom – častý problém, či vzácná komplikace? *Prakt. Lékáren.* 2022;18(2):75-78.
43. Vojtíšek P, Nalos D. Serotoninergní syndrom – kazuistika. *Anest Intenziv Mad.* 2011;22(3):159-162.
44. Werneke U, Truedson-Martiniussen P, Wikström H, Ott M. Serotonin syndrome: a clinical review of current controversies. *J Integr Neurosci.* 2020;19(4):719-727.
45. Zakharov S. Toxikologie nových rekreačních drog. Available from: https://postudium.cz/mod/book/view.php?id=1243 &chapterid=522.